A conclusive study was conducted for preparation and evaluation of combined inactivated entero-4 vaccine containing bovine rotavirus (BRV), bovine coronavirus (BCV), E. coli K99 and toxoid of C. perfringens type "C". Laboratory and field evaluations were conducted on laboratory animals, calves and late pregnant cows with monitoring the active and passive antibodies in vaccinated cows and their offspring respectively. Laboratory evaluation proved purity, safety and high efficacy of the vaccine without interference between different vaccine ingredients. Field evaluation gave satisfactory results when pregnant cows vaccinated at late stage of pregnancy with high neutralizing antibody titers against BRV, BCV and C. perfringens as well as high E. coli agglutinating titers. Maternal immunity passively protected offspring during the critical period of age and remained protected till the end of sampling time (30th day post parturition).